Does intravesical chemotherapy prevent invasive bladder cancer?

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Superficial bladder cancer poses a risk of recurrence and progression to invasive disease.
• Intravesical chemotherapy is a treatment modality used for bladder cancer.
• Previous studies suggest intravesical chemotherapy can prolong disease-free intervals and reduce recurrence rates.

Purpose of the Study:

• To evaluate the long-term efficacy of a 1-year course of intravesical chemotherapy in reducing tumor recurrence and progression to invasive carcinoma.
• To assess the impact of intravesical chemotherapy on the need for additional therapies and mortality in superficial bladder cancer patients.

Main Methods:

• A randomized multicenter protocol involving 123 patients treated between 1975 and 1978.
• Patients received either a 1-year course of thiotepa or VM26 intravesical chemotherapy or transurethral resection alone.
• Mean follow-up duration was 47 months.

Main Results:

• While tumor recurrence rates per patient-month were not statistically different, intravesical chemotherapy showed a trend towards lower recurrence (5.25-5.71 vs. 7.98).
• Significantly fewer patients receiving intravesical chemotherapy required additional treatment (15%) compared to controls (28%).
• Mortality from advanced bladder cancer was substantially lower in the intravesical chemotherapy group (3%) versus controls (19%).

Conclusions:

• A 1-year course of intravesical chemotherapy is associated with a significant decrease in the incidence of tumor progression in superficial bladder cancer.
• Intravesical chemotherapy demonstrates a favorable long-term impact on disease management and survival.
• These findings justify further trials with extended follow-up to confirm the long-term benefits.